The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.
The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.
复制标题
促卵泡激素受体：泌尿生殖系统恶性肿瘤的新靶点。
DOI：
10.1016/j.urolonc.2012.03.005
复制
发表时间：
2013-11
期刊：
影响因子：
--
通讯作者：
Galsky MD
中科院分区：
文献类型：
--
作者：
Gartrell BA;Tsao CK;Galsky MD
促卵泡激素（FSH）是哺乳动物生殖生物学中的一种中心激素。FSH受体（FSHR）以前被认为主要在卵巢和睾丸中表达，最近发现在许多实体瘤类型的肿瘤血管中表达，包括前列腺癌，尿路上皮癌和肾细胞癌。虽然FSHR在肿瘤血管中的生物学意义尚未阐明，但FSHR可能有助于新血管生成。据报道，FSHR由前列腺癌细胞表达，因此，在前列腺癌中靶向FSHR可能具有特别的效用。本文就FSHR在肿瘤血管中的发现及在泌尿生殖系统恶性肿瘤中的应用作一综述。我们还讨论了使FSHR成为治疗和成像目的的有吸引力的靶点的特征，以及FSHR作为泌尿生殖系统癌症的预后和/或预测生物标志物的潜在效用。© 2013 Elsevier Inc. All rights reserved.
Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. The FSH receptor (FSHR), which was previously believed to be expressed primarily in the ovary and testis, was recently found to be expressed in the tumor blood vessels of many solid tumor types, including prostate adenocarcinoma, urothelial carcinoma, and renal cell carcinoma. While the biologic significance of FSHR in tumor blood vessels has yet to be elucidated, FSHR may contribute to neoangiogenesis. FSHR has been reported to be expressed by prostate cancer cells and, thus, targeting FSHR in prostate cancer may be of particular utility. In this report, we discuss the finding of FSHR in tumor blood vessels and review the literature concerning FSHR in genitourinary malignancy. We also discuss the features that make FSHR an appealing target for therapeutic and imaging purposes and the potential utility of FSHR as a prognostic and/or predictive biomarker in genitourinary cancers. © 2013 Elsevier Inc. All rights reserved.